Immucell Stock Analysis

ImmuCell Stock Analysis Notes

About 40.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity recorded a loss per share of 0.49. The firm had not issued any dividends in recent years. ImmuCell had 1:100 split on the 25th of July 1990. ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people. To learn more about ImmuCell call Michael Brigham at 207 878 2770 or check out https://immucell.com.

ImmuCell Investment Alerts

ImmuCell Upcoming and Recent Events

ImmuCell Largest EPS Surprises

View All Earnings Estimates

ImmuCell Environmental, Social, and Governance (ESG) Scores

ImmuCell Stock Institutional Investors

Note, although ImmuCell's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ImmuCell Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.08 M.

ImmuCell Profitablity

The company has Profit Margin (PM) of (0.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25.

Management Efficiency

ImmuCell has return on total asset (ROA) of (0.0487) % which means that it has lost $0.0487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.161) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.13. The current year's Return On Capital Employed is expected to grow to -0.14. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 36.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 54.8 K.

Technical Drivers

As of the 27th of November, ImmuCell retains the Downside Deviation of 2.59, risk adjusted performance of 0.024, and Market Risk Adjusted Performance of (0.06). ImmuCell technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

ImmuCell Price Movement Analysis

ImmuCell Insider Trading Activities

ImmuCell Outstanding Bonds

ImmuCell Predictive Daily Indicators

ImmuCell Corporate Filings

ImmuCell Forecast Models

ImmuCell's time-series forecasting models are one of many ImmuCell's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ImmuCell's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how ImmuCell prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ImmuCell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ImmuCell. By using and applying ImmuCell Stock analysis, traders can create a robust methodology for identifying ImmuCell entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ImmuCell analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ImmuCell analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ImmuCell stock analysis indicators help investors evaluate how ImmuCell stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ImmuCell shares will generate the highest return on investment. By understating and applying ImmuCell stock analysis, traders can identify ImmuCell position entry and exit signals to maximize returns.

When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.